251
Participants
Start Date
September 29, 2016
Primary Completion Date
February 14, 2019
Study Completion Date
August 8, 2019
Liraglutide
Administered once daily subcutaneously (s.c., under the skin)
Placebo
Administered once daily subcutaneously (s.c., under the skin)
Novo Nordisk Investigational Site, Brussels
Novo Nordisk Investigational Site, Brussels
Novo Nordisk Investigational Site, Edegem
Novo Nordisk Investigational Site, Leuven
Novo Nordisk Investigational Site, Hasselt
Novo Nordisk Investigational Site, Namur
Novo Nordisk Investigational Site, Buffalo
Novo Nordisk Investigational Site, Pittsburgh
Novo Nordisk Investigational Site, Baltimore
Novo Nordisk Investigational Site, Charleston
Novo Nordisk Investigational Site, Goose Creek
Novo Nordisk Investigational Site, Greenville
Novo Nordisk Investigational Site, Memphis
Novo Nordisk Investigational Site, Columbus
Novo Nordisk Investigational Site, Dayton
Novo Nordisk Investigational Site, Dayton
Novo Nordisk Investigational Site, Minneapolis
Novo Nordisk Investigational Site, Puebla City
Novo Nordisk Investigational Site, Meridian
Novo Nordisk Investigational Site, Ciudad Madero
Novo Nordisk Investigational Site, Moscow
Novo Nordisk Investigational Site, Saint Petersburg
Novo Nordisk Investigational Site, Rostov-on-Don
Novo Nordisk Investigational Site, Stavropol
Novo Nordisk Investigational Site, Samara
Novo Nordisk Investigational Site, Ufa
Novo Nordisk Investigational Site, Novosibirsk
Novo Nordisk Investigational Site, Tomsk
Novo Nordisk Investigational Site, Baton Rouge
Novo Nordisk Investigational Site, Gothenburg
Novo Nordisk Investigational Site, Huddinge
Novo Nordisk Investigational Site, Malmo
Novo Nordisk Investigational Site, Uppsala
Lead Sponsor
Novo Nordisk A/S
INDUSTRY